A Phase 3 interventional study of RAD001 and Placebo in Tuberous Sclerosis Complex-associated Refractory Seizures, sponsored by Novartis Pharmaceuticals. Completed at 104 sites in 25 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-11-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Seizures by Novartis — none open to participants now, 1 under way, 1 of them phase 3. Seizures · Novartis.
Among the 11 studies in Seizures by Novartis, this one has the largest enrollment, is the only one that started in 2013, is one of 5 in phase 3, and was the 10th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →None of the 11 studies in Seizures by Novartis is open now. The open studies under Seizures, anywhere →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 2 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 6 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 94 across the 11 interventional studies. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Seizures by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Seizures by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.
The study consisted of 4 phases for each patient Baseline phase:[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)], Core phase [from randomization at Week 0 (V2) to Week 18 (V11)], Extension phase [from Week 18 (V11) until 48 weeks after the last patient had completed the core phase] and Post Extension phase [from end of Extension phase to end of study].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female between the ages of 2 and 65 years (except in Europe where minimum age will be 1).
Prior epilepsy surgery is allowed if performed at least 12 months before study entry.
<!-- -->
≥ 1,000/mm3 9. Written informed consent. Subjects or their legal guardians must have the ability to comprehend the informed consent form and be willing to provide informed consent.
Exclusion Criteria:
Patients with seizures secondary to metabolic, toxic, infectious or psychogenic disorder or drug abuse or current seizures related to an acute medical illness.
A known history of seropositivity or other active viral infections. 12. Patients with an active, bleeding diathesis. 13. Patient with uncontrolled hyperlipidemia: fasting serum cholesterol > 300 mg/dL OR >7.75 mmol/L AND fasting triglycerides > 2.5 x ULN.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.
Drug: RAD001 · Drug: Antiepileptic drug (1 to 3 only) · Drug: open label RAD001 (only used for post-extension phase)
Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.
Drug: RAD001 · Drug: Antiepileptic drug (1 to 3 only) · Drug: open label RAD001 (only used for post-extension phase)
Participants received placebo plus 1 to 3 antiepileptic drugs.
Drug: Placebo · Drug: Antiepileptic drug (1 to 3 only) · Drug: open label RAD001 (only used for post-extension phase)
Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
Also known as: everolimus
Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
Also known as: open label everolimus
Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate
Comparison of response rates in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. Response means at least a 50% reduction from baseline in partial-onset seizure frequency during the maintenance period of the core phase.
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency
Comparison of median percent change from baseline in weekly seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase (SFcfb) = 100 × (SFB - SFM) ÷ SFB where: SFB is the average weekly seizure frequency in the Baseline phase SFM is the average weekly seizure frequency in the maintenance period of the Core phase A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Percentage of Seizure-free Patients During the Maintenance Period of the Core Phase
Comparison of seizure freedom (100% reduction in seizure frequency) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Seizure free means a 100% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Core Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency
Comparison of percentage of patients with at least ≥ 25% reduction in seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. At least 25% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Core Phase: Distribution of Reduction From Baseline in Seizure Frequency
Comparison of percentage of patients in six categories of seizure reduction from baseline (≤ -25% (exacerbation); \> -25% to \< 25% (no change); ≥ 25% to \< 50%; ≥ 50% to \< 75%; ≥ 75% to \< 100%; 100% (seizure-freedom)) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Core Phase: Changes From Baseline in Number of Seizure-free Days
Comparison of seizure-free days relative to baseline in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Core Phase: Probability That a Patient Remains On-treatment up to a Specified Time Point
Comparison of time to treatment discontinuation in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during the core phase. Treatment duration is defined as the time from randomization until the date of permanent study treatment discontinuation (for any reason) at any time during the Core phase. The percentage event-free probability estimate is the estimated probability that a patient will remain on-treatment up to a specified time point (Week 6, 12, 18)
Time frame: Week 6, Week 12, Week 18
Core Phase: Change From Baseline in the QOLCE Overall Quality-of-life Score for Patients <11 Years
Comparison of quality of life in the everolimus (from 3 age specific questionnaires) low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life Childhood Epilepsy (QOLCE) questionnaire, used for patients \< 11 years at baseline, was completed by the patient's parent or caregiver. It consists of 16 subscales (13 multi-item scales and 3 single item scales) and one overall quality-of-life score. Scores range from 0-100, with higher scores corresponding to improved QoL. The Overall Quality of Life Score is computed by adding each subscale score for each individual and then dividing by 16.
Time frame: Baseline, Week 18
Core Phase: Change From Baseline in the QOLIE-AD-48 Overall Quality-of-life Score for Patients >=11 to 18 Years
Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory for Adolescents-48 (QOLIE-AD-48) is a survey of health-related quality of life for adolescents 11 to 18 years of age with epilepsy. The QOLIE-AD-48 is completed by the patient. It contains 48 items which assess 8 subscales. Scores range from 0-100, with higher scores corresponding to improved QoL. The overall quality of life score is obtained by summing a linear combination of the 8 subscale scores, where each subscale is multiplied by a relative weight that is provided in the original publication.
Time frame: Baseline, Week 18
Core Phase: Change From Baseline in the QOLIE-31-P Overall Quality-of-life Score for Patients Aged >=18 Years
Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory-31-Problems (QOLIE-31-P) is a survey of health-related quality of life for adults with epilepsy. The QOLIE-31-P is completed by the patient. It contains 39 items, of which a total of 30 are used to make up 7 different subscales. Scores range from 0-100, with higher scores indicating a greater level of functioning and QoL. The overall quality of life score is obtained by summing a linear combination of the 7 subscale scores, where each subscale is multiplied by a relative weight that is obtained from the patient's answer to 7 items of this questionnaire.
Time frame: Baseline, Week 18
Core Phase: Change From Baseline in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score
Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.
Time frame: Baseline, 18 weeks
Long Term Evaluation: Effect of Everolimus Over Time in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score
Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.
Time frame: Baseline, Weeks 18, 42, 66 and 90
Core Phase: Change From Baseline in Wechsler Nonverbal Composite Score
The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range.
Time frame: Baseline, Week 18
Long Term Evaluation: Effect of Everolimus Over Time in the Overall Wechsler Nonverbal Composite Score
The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range
Time frame: Baseline, Weeks 18, 42, 66 and 90
Core Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration
Comparison of response rate in seizure frequency for 5 categories of time-normalized minimum concentration (Cmin, TN) (\< 3 ng/mL; 3-7 ng/mL; \>7-\<9 ng/mL; 9-15 ng/mL; \>15 ng/mL). Response rate is the percentage of patients with ≥ 50% reduction from baseline in average weekly partial-onset seizure frequency during the maintenance period of the Core phase.
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Core Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration
Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase is calculated as follow: (SFcfb) = 100 × (SFB - SFM) ÷ SFB where SFB is the average weekly seizure frequency in the Baseline phase and SFM is the average weekly seizure frequency in the maintenance period of the Core phase. A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.
Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Long Term Evaluation: Relationship Between Seizure Frequency and Time-normalized Everolimus Concentration at Trough (Cmin,TN) - Repeated Measures Analysis
A repeated measures analysis considering fixed 2-week intervals and including the level of exposure (time-normalized Cmin values), the time on-treatment and the seizure frequency at baseline quantified the estimated percentage change over 2 weeks in seizure frequency associated with a double exposure to everolimus, 15 days more on treatment and half the seizure frequency at baseline. A positive percentage change means a reduction in seizure frequency whereas a negative percentage change means an increase in seizure frequency.
Time frame: During everolimus treatment from start of everolimus up to the end of the extension phase, an average of 1.7 year
Core Phase: Impact of Everolimus on Anti-epileptic Drugs (AEDs) Concentrations
Impact of everolimus on AED concentrations at trough. Pre-dose plasma samples to measure AED concentrations were measured at at Visits 1 (Screening), 2 (Baseline), 3, and 5. Effects of everolimus on the exposure of antiepileptic drugs was assessed by comparing the anti-epileptic drug concentrations at Visits 1 and 2 (AEDs alone) and at Visits 3 and 5 (AEDs plus everolimus).
Time frame: Baseline, Weeks 1 & 3
Long Term Evaluation: Percentage Change From Start of Everolimus in Seizure Frequency by Time Window
Percentage change from start of everolimus in average weekly seizure frequency (SFcfe) = 100 × (SFe - SFtw) ÷ SFe where: SFe is the average weekly seizure frequency in the 8-week period before start of everolimus SFtw is the average weekly seizure frequency in a 12-week time window A positive percentage change from start of everolimus (SFcfe) means a reduction in seizure frequency whereas a negative percentage change from start of everolimus (SFcfe) means an increase in seizure frequency.
Time frame: Baseline (8-week period before start of everolimus), Week 7 to 18, Week 19 to 30, and 12 weeks thereafter up to Week 102
Seizure Free Rates by Time Window
Percentage of seizure-free participants for each 12-week time window.
Time frame: Weeks 18, 30, 42, 54, 66, 78, 90 & 102
Core Phase: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes
Comparison of suicidality using the C-SSRS in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire used for suicide assessment developed by multiple institutions, including Columbia University, with NIMH support. The scale is evidence-supported and is part of a national and international public health initiative involving the assessment of suicidality. There are different scoring systems depending on the population. The important elements to note are that the higher the scores on the individual items and the more "yes" items, the higher the suicide risk.
Time frame: Baseline, Week 18
Long Term Evaluation: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes
The C-SSRS was completed at each visit. The table below presents the number of patients who reported at least one completed suicide, one suicide attempt, one preparatory action toward imminent suicidal behavior, one suicidal ideation and one self-injurious behavior without suicidal intent at any time point after starting everolimus.
Time frame: During everolimus treatment from start of everolimus up to permanent discontinuation of everolimus, an average of 2.3 years
355 patients were planned to be enrolled and a total of 366 patients were randomized: 117 to the everolimus targeted low-trough arm (LT), 130 to the everolimus targeted high-trough (HT) arm, and 119 to treatment with placebo.
| Milestone | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Started | 117 | 130 | 119 |
| Completed core phase | 110 | 122 | 114 |
| Continued in ext. phase | 110 | 119 | 114 |
| Completed ext. phase | 79 | 92 | 81 |
| Continued in post-ext. phase | 78 | 90 | 81 |
| Completed post-ext phase | 74 | 85 | 75 |
| Did not continue in ext phase | 0 | 3 | 0 |
| Did not cont. in post-ext phase | 1 | 2 | 0 |
| Completed | 74 | 85 | 75 |
| Not completed | 43 | 45 | 44 |
| Withdrew: Death | 0 | 2 | 2 |
| Withdrew: Adverse event | 19 | 14 | 13 |
| Withdrew: Withdrawal by subject | 12 | 12 | 8 |
| Withdrew: Lack of efficacy | 8 | 8 | 14 |
| Withdrew: Protocol violation | 2 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Administrative problems | 1 | 0 | 0 |
| Withdrew: Did not continue in ext | 0 | 3 | 0 |
| Withdrew: Did not continue in post-ext. phase | 1 | 2 | 0 |
| Withdrew: Patients never switched to everolimus | 0 | 0 | 5 |
Comparison of response rates in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. Response means at least a 50% reduction from baseline in partial-onset seizure frequency during the maintenance period of the core phase.
| Percentage of responders | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate | 28.2 (20.3 to 37.3) | 40.0 (31.5 to 49.0) | 15.1 (9.2 to 22.8) |
Comparison of median percent change from baseline in weekly seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase (SFcfb) = 100 × (SFB - SFM) ÷ SFB where: SFB is the average weekly seizure frequency in the Baseline phase SFM is the average weekly seizure frequency in the maintenance period of the Core phase A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.
| Percentage change from baseline | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency | 29.29 (18.82 to 41.88) | 39.55 (35.03 to 48.74) | 14.86 (0.11 to 21.71) |
Comparison of seizure freedom (100% reduction in seizure frequency) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Seizure free means a 100% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.
| Percentage of seizure-free participants | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Percentage of Seizure-free Patients During the Maintenance Period of the Core Phase | 5.1 (1.9 to 10.8) | 3.8 (1.3 to 8.7) | 0.8 (0.0 to 4.6) |
Comparison of percentage of patients with at least ≥ 25% reduction in seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. At least 25% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.
| Percentage of participants | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Core Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency | 52.1 (42.7 to 61.5) | 70.0 (61.3 to 77.7) | 37.8 (29.1 to 47.2) |
Comparison of percentage of patients in six categories of seizure reduction from baseline (≤ -25% (exacerbation); \> -25% to \< 25% (no change); ≥ 25% to \< 50%; ≥ 50% to \< 75%; ≥ 75% to \< 100%; 100% (seizure-freedom)) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase
| Percentage of participants | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| 100% (seizure free) | 5.1 | 3.8 | 0.8 |
| ≥ 75 to <100 (75% responder) | 6.0 | 15.4 | 5.0 |
| ≥ 50 to <75 (50% responder) | 17.1 | 20.8 | 9.2 |
| ≥ 25 to <50 (25% responder) | 23.9 | 30.0 | 22.7 |
| >-25 to <25 (No change) | 35.0 | 18.5 | 41.2 |
| ≤ -25 (Exacerbation) | 12.8 | 11.5 | 20.2 |
| Missing (missing) | 0.0 | 0.0 | 0.8 |
Comparison of seizure-free days relative to baseline in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase
| Number of seizure-free days -per 28 days | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Core Phase: Changes From Baseline in Number of Seizure-free Days | 2.00 (-23.1 to 27.7) | 4.01 (-10.0 to 27.5) | 0.47 (-13.4 to 21.8) |
Comparison of time to treatment discontinuation in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during the core phase. Treatment duration is defined as the time from randomization until the date of permanent study treatment discontinuation (for any reason) at any time during the Core phase. The percentage event-free probability estimate is the estimated probability that a patient will remain on-treatment up to a specified time point (Week 6, 12, 18)
| Percentage event-free prob. estimates | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Week 6 | 97.4 (92.3 to 99.2) | 96.2 (91.0 to 98.4) | 99.2 (94.2 to 99.9) |
| Week 12 | 95.7 (90.0 to 98.2) | 95.4 (90.0 to 97.9) | 97.5 (92.4 to 99.2) |
| Week 18 | 70.1 (60.9 to 77.5) | 71.5 (62.9 to 78.5) | 75.6 (66.9 to 82.4) |
Comparison of quality of life in the everolimus (from 3 age specific questionnaires) low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life Childhood Epilepsy (QOLCE) questionnaire, used for patients \< 11 years at baseline, was completed by the patient's parent or caregiver. It consists of 16 subscales (13 multi-item scales and 3 single item scales) and one overall quality-of-life score. Scores range from 0-100, with higher scores corresponding to improved QoL. The Overall Quality of Life Score is computed by adding each subscale score for each individual and then dividing by 16.
| scores on a scale | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Baseline | 52.3 (26 to 75) | 56.5 (26 to 76) | 55.3 (33 to 74) |
| End of Core Phase | 53.6 (24 to 79) | 59.5 (36 to 78) | 57.2 (20 to 77) |
| Change from Baseline | 0.2 (-25 to 24) | 0.0 (-19 to 18) | 1.0 (-18 to 28) |
Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory for Adolescents-48 (QOLIE-AD-48) is a survey of health-related quality of life for adolescents 11 to 18 years of age with epilepsy. The QOLIE-AD-48 is completed by the patient. It contains 48 items which assess 8 subscales. Scores range from 0-100, with higher scores corresponding to improved QoL. The overall quality of life score is obtained by summing a linear combination of the 8 subscale scores, where each subscale is multiplied by a relative weight that is provided in the original publication.
| scores on a scale | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Baseline | 56.1 (43 to 86) | 58.8 (35 to 81) | 59.6 (13 to 88) |
| End of Core Phase | 58.5 (47 to 89) | 60.7 (46 to 74) | 65.4 (29 to 87) |
| Change from Baseline | 4.7 (-11 to 11) | 5.8 (-13 to 38) | 7.2 (-18 to 25) |
Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory-31-Problems (QOLIE-31-P) is a survey of health-related quality of life for adults with epilepsy. The QOLIE-31-P is completed by the patient. It contains 39 items, of which a total of 30 are used to make up 7 different subscales. Scores range from 0-100, with higher scores indicating a greater level of functioning and QoL. The overall quality of life score is obtained by summing a linear combination of the 7 subscale scores, where each subscale is multiplied by a relative weight that is obtained from the patient's answer to 7 items of this questionnaire.
| scores on a scale | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Baseline | 39.5 (13 to 64) | 43.2 (5 to 89) | 43.6 (11 to 83) |
| End of Core Phase | 48.6 (11 to 54) | 37.1 (6 to 97) | 54.8 (26 to 90) |
| Change from Baseline | -0.5 (-17 to 34) | 0.4 (-47 to 20) | 5.3 (-16 to 36) |
Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.
| scores on a scale | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Baseline | 58.00 (20.0 to 112.0) | 56.50 (20.0 to 102.0) | 55.00 (20.0 to 103.0) |
| End of Core Phase | 54.00 (6.0 to 121.0) | 55.00 (20.0 to 111.0) | 55.00 (20.0 to 105.0) |
| Change from Baseline | -1.00 (-21.0 to 15.0) | 0.00 (-13.0 to 15.0) | 0.00 (-12.0 to 10.0) |
Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.
| scores on a scale | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Everolimus Long Term Evaluation (LTE) |
|---|---|---|---|---|
| Baseline | — | — | — | 56.00 (20.0 to 112.0) |
| Week 18 | — | — | — | 53.50 (4.0 to 121.0) |
| Week 42 | — | — | — | 55.50 (20.0 to 111.0) |
| Week 66 | — | — | — | 57.00 (20.0 to 112.0) |
| Week 90 | — | — | — | 49.50 (20.0 to 150.0) |
The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range.
| scores on a scale | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Everolimus Long Term Evaluation (LTE) |
|---|---|---|---|---|
| Baseline | -0.48 (-2.3 to 8.1) | -0.69 (-2.3 to 9.6) | -1.11 (-2.3 to 8.3) | — |
| End of Core Phase | -0.04 (-2.3 to 8.1) | -0.89 (-2.3 to 7.5) | -0.51 (-2.3 to 10.1) | — |
| Change from Baseline | 0.00 (-2.5 to 1.6) | 0.00 (-10.0 to 2.1) | 0.00 (-3.3 to 1.7) | — |
The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range
| scores on a scale | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Everolimus Long Term Evaluation (LTE) |
|---|---|---|---|---|
| Baseline | — | — | — | -0.53 (-2.3 to 10.1) |
| Week 18 | — | — | — | -0.44 (-2.3 to 9.5) |
| Week 42 | — | — | — | -0.36 (-2.3 to 10.8) |
| Week 66 | — | — | — | 0.13 (-2.3 to 9.1) |
| Week 90 | — | — | — | -0.06 (-2.3 to 9.0) |
Comparison of response rate in seizure frequency for 5 categories of time-normalized minimum concentration (Cmin, TN) (\< 3 ng/mL; 3-7 ng/mL; \>7-\<9 ng/mL; 9-15 ng/mL; \>15 ng/mL). Response rate is the percentage of patients with ≥ 50% reduction from baseline in average weekly partial-onset seizure frequency during the maintenance period of the Core phase.
| Percentage of responders | <3 ng/mL | 3-7 ng/mL | >7-<9 ng/mL | 9-15 ng/mL | >15 ng/mL |
|---|---|---|---|---|---|
| Core Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration | 14.3 (1.8 to 42.8) | 29.9 (22.7 to 38.0) | 44.2 (30.5 to 58.7) | 50.0 (31.3 to 68.7) | 50.0 (1.3 to 98.7) |
Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase is calculated as follow: (SFcfb) = 100 × (SFB - SFM) ÷ SFB where SFB is the average weekly seizure frequency in the Baseline phase and SFM is the average weekly seizure frequency in the maintenance period of the Core phase. A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.
| Percentage change | <3 ng/mL | 3-7 ng/mL | >7-<9 ng/mL | 9-15 ng/mL | >15 ng/mL |
|---|---|---|---|---|---|
| Core Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration | 20.55 (-8.45 to 35.39) | 35.56 (24.43 to 41.88) | 39.72 (28.02 to 62.79) | 47.69 (36.46 to 66.32) | 61.56 (42.73 to 80.38) |
A repeated measures analysis considering fixed 2-week intervals and including the level of exposure (time-normalized Cmin values), the time on-treatment and the seizure frequency at baseline quantified the estimated percentage change over 2 weeks in seizure frequency associated with a double exposure to everolimus, 15 days more on treatment and half the seizure frequency at baseline. A positive percentage change means a reduction in seizure frequency whereas a negative percentage change means an increase in seizure frequency.
| % change over 2-wk in seizures freq. | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Everolimus Long Term Evaluation (LTE) |
|---|---|---|---|---|
| By doubling the time-normalized Cmin (log scale) | — | — | — | 8.93 (6.87 to 10.95) |
| By reporting half the seizure freq. at baseline | — | — | — | 48.82 (46.37 to 51.15) |
| By adding 12 weeks on treatmen | — | — | — | 6.42 (4.53 to 8.27) |
Impact of everolimus on AED concentrations at trough. Pre-dose plasma samples to measure AED concentrations were measured at at Visits 1 (Screening), 2 (Baseline), 3, and 5. Effects of everolimus on the exposure of antiepileptic drugs was assessed by comparing the anti-epileptic drug concentrations at Visits 1 and 2 (AEDs alone) and at Visits 3 and 5 (AEDs plus everolimus).
| ng/mL | Valporic Acid | Carbamazepine | Clobazam | N-desmethylclobazam | Topiramate | TRI477 | TRI476 | Clonazepam | Zonisamide | Phenobarbital | Phenytoin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Core Phase: Impact of Everolimus on Anti-epileptic Drugs (AEDs) Concentrations | 0.962 (0.913 to 1.014) | 1.108 (1.016 to 1.208) | 1.093 (1.037 to 1.153) | 1.071 (1.017 to 1.127) | 0.983 (0.872 to 1.108) | 1.086 (0.913 to 1.291) | 1.194 (0.936 to 1.523) | 1.065 (0.974 to 1.163) | 1.028 (0.971 to 1.089) | 0.957 (0.886 to 1.034) | 1.020 (0.874 to 1.190) |
Percentage change from start of everolimus in average weekly seizure frequency (SFcfe) = 100 × (SFe - SFtw) ÷ SFe where: SFe is the average weekly seizure frequency in the 8-week period before start of everolimus SFtw is the average weekly seizure frequency in a 12-week time window A positive percentage change from start of everolimus (SFcfe) means a reduction in seizure frequency whereas a negative percentage change from start of everolimus (SFcfe) means an increase in seizure frequency.
| Percent change | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Everolimus Long Term Evaluation (LTE) |
|---|---|---|---|---|
| Week 18 | — | — | — | 31.65 (28.51 to 36.09) |
| Week 30 | — | — | — | 35.74 (29.37 to 39.06) |
| Week 42 | — | — | — | 42.86 (34.44 to 48.15) |
| Week 54 | — | — | — | 46.05 (39.93 to 53.61) |
| Week 66 | — | — | — | 49.07 (38.26 to 55.56) |
| Week 78 | — | — | — | 51.69 (43.88 to 61.58) |
| Week 90 | — | — | — | 57.33 (47.37 to 67.01) |
| Week 102 | — | — | — | 59.69 (52.13 to 70.94) |
Percentage of seizure-free participants for each 12-week time window.
| Percentage of seizure-free participants | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Everolimus Long Term Evaluation (LTE) |
|---|---|---|---|---|
| Week 18 | — | — | — | 3.98 (2.2 to 6.6) |
| Week 30 | — | — | — | 6.87 (4.4 to 10.1) |
| Week 42 | — | — | — | 8.44 (5.6 to 12.0) |
| Week 54 | — | — | — | 8.70 (5.8 to 12.5) |
| Week 66 | — | — | — | 10.99 (7.6 to 15.2) |
| Week 78 | — | — | — | 13.49 (9.5 to 18.3) |
| Week 90 | — | — | — | 14.86 (10.5 to 20.2) |
| Week 102 | — | — | — | 15.18 (10.4 to 21.1) |
Comparison of suicidality using the C-SSRS in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire used for suicide assessment developed by multiple institutions, including Columbia University, with NIMH support. The scale is evidence-supported and is part of a national and international public health initiative involving the assessment of suicidality. There are different scoring systems depending on the population. The important elements to note are that the higher the scores on the individual items and the more "yes" items, the higher the suicide risk.
| Participants | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo |
|---|---|---|---|
| Completed suicide | 0 | 0 | 0 |
| Suicide attempt | 1 | 0 | 0 |
| Prep actions toward imminent suicidal behavior | 2 | 0 | 0 |
| Suicidal ideation | 3 | 1 | 0 |
| Self-injurious behavior without suicide intent | 0 | 0 | 0 |
The C-SSRS was completed at each visit. The table below presents the number of patients who reported at least one completed suicide, one suicide attempt, one preparatory action toward imminent suicidal behavior, one suicidal ideation and one self-injurious behavior without suicidal intent at any time point after starting everolimus.
| Participants | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Everolimus Long Term Evaluation (LTE) |
|---|---|---|---|---|
| Completed suicide | — | — | — | 0 |
| Suicidal attempt | — | — | — | 1 |
| Prep. actions toward imminent suicidal behavior | — | — | — | 2 |
| Suicidal ideation | — | — | — | 7 |
| Self-injurious behavior without suicide intent | — | — | — | 1 |
Collected over Adverse Events were collected during everolimus treatment from start of everolimus up to permanent discontinuation of everolimus, an average of 2.3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus LT Target of 3 to 7 ng/mL | 1/117 (0.9%) | 50/117 (42.7%) | 110/117 (94%) |
| Everolimus HT Target of 9 to 15 ng/mL | 2/130 (1.5%) | 49/130 (37.7%) | 126/130 (96.9%) |
| Everolimus Start Ext | 1/114 (0.9%) | 38/114 (33.3%) | 109/114 (95.6%) |
| Everolimus All | 4/361 (1.1%) | 137/361 (38%) | 345/361 (95.6%) |
| Event | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Everolimus Start Ext | Everolimus All |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 16/117 | 13/130 | 9/114 | 38/361 |
| SeizureNervous system disorders | 7/117 | 7/130 | 4/114 | 18/361 |
| Status epilepticusNervous system disorders | 7/117 | 6/130 | 2/114 | 15/361 |
| PyrexiaGeneral disorders | 5/117 | 4/130 | 2/114 | 11/361 |
| GastroenteritisInfections and infestations | 5/117 | 5/130 | 4/114 | 14/361 |
| TonsillitisInfections and infestations | 0/117 | 2/130 | 3/114 | 5/361 |
| Viral infectionInfections and infestations | 0/117 | 0/130 | 3/114 | 3/361 |
| DiarrhoeaGastrointestinal disorders | 3/117 | 2/130 | 0/114 | 5/361 |
| Mouth ulcerationGastrointestinal disorders | 3/117 | 0/130 | 1/114 | 4/361 |
| InfluenzaInfections and infestations | 3/117 | 1/130 | 2/114 | 6/361 |
| Event | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Everolimus Start Ext | Everolimus All |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 47/117 | 56/130 | 31/114 | 134/361 |
| DiarrhoeaGastrointestinal disorders | 45/117 | 42/130 | 30/114 | 117/361 |
| StomatitisGastrointestinal disorders | 41/117 | 48/130 | 41/114 | 130/361 |
| Mouth ulcerationGastrointestinal disorders | 36/117 | 44/130 | 22/114 | 102/361 |
| Upper respiratory tract infectionInfections and infestations | 32/117 | 42/130 | 22/114 | 96/361 |
| NasopharyngitisInfections and infestations | 33/117 | 35/130 | 26/114 | 94/361 |
| VomitingGastrointestinal disorders | 28/117 | 35/130 | 16/114 | 79/361 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/117 | 33/130 | 15/114 | 77/361 |
| Aphthous ulcerGastrointestinal disorders | 11/117 | 23/130 | 10/114 | 44/361 |
| HeadacheNervous system disorders | 19/117 | 19/130 | 10/114 | 48/361 |
Full Analysis Set: The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization.
| Age, Continuous(years) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| Median | 9.72 (2.2 to 56.3) | 10.08 (2.3 to 50.5) | 10.34 (2.2 to 52.0) | 10.06 (2.2 to 56.3) |
| Age, Customized(Participants) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| < 6 years | 33 | 37 | 34 | 104 |
| 6 to <12 years | 37 | 39 | 37 | 113 |
| 12 to <18 years | 26 | 31 | 25 | 82 |
| 18 to <65 years | 21 | 23 | 23 | 67 |
| Sex: Female, Male(Participants) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| Female | 53 | 65 | 58 | 176 |
| Male | 64 | 65 | 61 | 190 |
| Race/Ethnicity, Customized(Participants) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| Caucasian | 76 | 84 | 77 | 237 |
| Asian | 29 | 31 | 27 | 87 |
| Black | 2 | 1 | 1 | 4 |
| Native American | 0 | 1 | 0 | 1 |
| Pacific Islander | 1 | 0 | 0 | 1 |
| Other | 9 | 13 | 14 | 36 |
| Weight(kg) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| Mean | 38.69 ± 22.802 | 40.75 ± 27.267 | 40.50 ± 24.923 | 40.01 ± 25.093 |
| Height(cm) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| Mean | 135.65 ± 26.171 | 136.25 ± 28.234 | 135.67 ± 27.097 | 135.87 ± 27.145 |
| Body surface area(m^2) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| Mean | 1.18 ± 0.437 | 1.20 ± 0.501 | 1.20 ± 0.476 | 1.20 ± 0.472 |
| Body mass index(kg/m^2) | Everolimus LT Target of 3 to 7 ng/mL | Everolimus HT Target of 9 to 15 ng/mL | Placebo | Total |
|---|---|---|---|---|
| Mean | 19.29 ± 5.283 | 19.56 ± 6.233 | 19.78 ± 5.484 | 19.55 ± 5.689 |
Showing the first 100 of 104 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2013 to primary completion in Oct 2017, 53 months.
Results were first posted in Nov 2018, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 53 months is close to that.
Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus